Neos Therapeutics Inc (NEOS) Shares Bought by Sphera Funds Management LTD.
Sphera Funds Management LTD. boosted its holdings in Neos Therapeutics Inc (NASDAQ:NEOS) by 136.2% during the third quarter, Holdings Channel reports. The institutional investor owned 831,697 shares of the company’s stock after buying an additional 479,555 shares during the period. Sphera Funds Management LTD.’s holdings in Neos Therapeutics were worth $4,034,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of the business. Stonepine Capital Management LLC bought a new stake in shares of Neos Therapeutics in the 3rd quarter worth approximately $1,105,000. JPMorgan Chase & Co. lifted its position in shares of Neos Therapeutics by 162.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 267,417 shares of the company’s stock worth $1,297,000 after acquiring an additional 165,555 shares during the period. Franklin Resources Inc. lifted its position in shares of Neos Therapeutics by 8.4% in the 3rd quarter. Franklin Resources Inc. now owns 2,493,239 shares of the company’s stock worth $12,092,000 after acquiring an additional 193,500 shares during the period. Bridgeway Capital Management Inc. lifted its position in shares of Neos Therapeutics by 41.6% in the 3rd quarter. Bridgeway Capital Management Inc. now owns 170,100 shares of the company’s stock worth $825,000 after acquiring an additional 50,000 shares during the period. Finally, BlackRock Inc. lifted its position in shares of Neos Therapeutics by 1.5% in the 3rd quarter. BlackRock Inc. now owns 2,122,751 shares of the company’s stock worth $10,295,000 after acquiring an additional 31,469 shares during the period. 45.12% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Alan L. Heller bought 43,478 shares of the company’s stock in a transaction dated Thursday, November 8th. The stock was acquired at an average cost of $2.30 per share, with a total value of $99,999.40. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 5.40% of the company’s stock.
Neos Therapeutics (NASDAQ:NEOS) last issued its earnings results on Friday, November 9th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.03). Neos Therapeutics had a negative return on equity of 586.25% and a negative net margin of 133.46%. The company had revenue of $12.50 million during the quarter, compared to analyst estimates of $14.80 million. Research analysts predict that Neos Therapeutics Inc will post -1.71 earnings per share for the current year.
NEOS has been the subject of a number of research reports. ValuEngine upgraded Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 18th. Cantor Fitzgerald reiterated a “buy” rating and issued a $20.00 price objective on shares of Neos Therapeutics in a research report on Friday, November 9th. Zacks Investment Research upgraded Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 11th. JMP Securities reduced their price objective on Neos Therapeutics from $22.00 to $10.00 and set a “market outperform” rating for the company in a research report on Monday, November 12th. Finally, Wells Fargo & Co reduced their price objective on Neos Therapeutics from $11.00 to $6.00 and set an “outperform” rating for the company in a research report on Wednesday, November 14th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $12.00.
COPYRIGHT VIOLATION NOTICE: “Neos Therapeutics Inc (NEOS) Shares Bought by Sphera Funds Management LTD.” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/neos-therapeutics-inc-neos-shares-bought-by-sphera-funds-management-ltd/2670942.html.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Further Reading: How analysts view the yield curve
Want to see what other hedge funds are holding NEOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neos Therapeutics Inc (NASDAQ:NEOS).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.